Pharmaceutical composition comprising an alpha-MSH analog selected from the group consisting of: [Nle4, D-Phe7] -alpha MSH [Nle4, D-Phe7] -alpha MSH4-10 [Nle4, D-Phe7] -alpha MSH4- 11 [Nle4, D-Phe7-D-Trp9] -alpha MSH4-11, or [Nle4, D-Phe7] -alpha MSH4-9 for use in the treatment or prevention of vitiligo in a human subject where the pharmaceutical composition is administered subcutaneously in a sustained release delivery system.Composición farmacéutica que comprende un análogo de alfa-MSH seleccionado del grupo que consiste de: [Nle4, D-Phe7]-alfa MSH [Nle4, D-Phe7]-alfa MSH4-10 [Nle4, D-Phe7]-alfa MSH4-11 [Nle4, D-Phe7-D-Trp9]-alfa MSH4-11, o [Nle4, D-Phe7]-alfa MSH4-9 para uso en el tratamiento o prevención del vitíligo en un sujeto humano en donde la composición farmacéutica es administrada por vía subcutánea en un sistema de suministro de liberación sostenida.
